Irvine, California– December 1, 2021 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the annual American Society of Hematology (ASH) meeting new data on the use of their proprietary machine learning approaches in the diagnosis of acute graft-versus-host disease (aGVHD) and for the stratifying of patients with diffuse large B-cell lymphoma (DLBCL) based on outcome after treatment with the standard R-CHOP. GTC will also present studies on their liquid biopsy and its reliability in detecting cytogenetic abnormalities in myeloid neoplasms and in monitoring minimal residual disease after stem cell transplant. These studies were performed in collaboration with multiple academic institutions that contributed clinical data. GTC is the only diagnostic company that offers molecular testing based on cooperative (Co-Op) business model. By working with other members of the Co-Op, the company is able to develop and validate tests in efficient ways reducing the cost of testing and innovation. GTC shares the intellectual property rights of three of the four innovative tests with John Theurer Cancer Center and Hackensack Meridian Health, both members of the Co-Op. Dr. Andre Goy, Chairman and Chief Physician Officer at John Theurer Cancer Center, Chairman of Oncology at Hackensack Meridian School of Medicine and Professor of Medicine at Georgetown University said “being a part of the cooperative group at GTC has been extremely productive and enabled John Theurer Cancer Center to offer state-of-the-art precision medicine, not only for selecting therapy but for developing cutting edge approaches for monitoring patients”.
The presented work reflects the current GTC innovation strategy in improving cancer care. GTC uses RNA data and targeted transcriptome generated by next generation sequencing (NGS) along with new machine learning approaches to predict the presence of aGVHD and for stratifying patients with DLBCL. These are examples of how genomics can improve patient care. aGVHD remains a major cause of morbidity and mortality in patients after hematopoietic stem cell transplant. Proper and early diagnosis of this serious complication of transplant will trigger prophylaxis therapy and treatment that may improve outcome. Similarly predicting patients with DLBCL who will not respond well to the current standard R-CHOP therapy will help in selecting different therapeutic approaches and new clinical trials.
GTC is developing new indications in liquid biopsy testing and extensively exploring new technology to improve patient care. ASH presentations show that their liquid biopsy can reliably predict cytogenetic abnormalities in patient with hematologic neoplasms and can be used for diagnosis and management of patients with myeloid neoplasm. Another presentation shows that liquid biopsy is reliable in monitoring patients after hematopoietic stem cell transplant. Dr. Maher Albitar, founder, chief medical officer, and chief executive officer of GTC stated “GTC was established as a co-op business to improve patient and democratizing genomics through efficient innovation and collaboration”. He added “Advances in genomics and machine learning are opening new opportunities in medicine to improve outcome in cancer care. Our new studies that are presented at ASH are examples of how a cooperative business model can deliver”.
Following are the list and dates and times of the presentations:
1) Reliability of Liquid Biopsy and Next Generation Sequencing in Monitoring Residual Disease Post-Hematopoietic Stem Cell Transplant, Saturday, December 11, 2021: 5:30 PM-7:30 PM
2) Bone Marrow-Based Biomarkers for Predicting aGVHD Using Targeted RNA Next Generation Sequencing and Machine Learning , Sunday, December 12, 2021: 6:00 PM-8:00 PM
3) Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms; Sunday, December 12, 2021: 6:00 PM-8:00 PM
4) Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms; Monday, December 13, 2021: 6:00 PM-8:00 PM
About Genomic Testing Cooperative, LCA
Genomic Testing Cooperative (GTC) is a privately-owned molecular testing company located in Irvine, CA. The company operates based on a cooperative (co-op) business model. Members of the co-op hold type A shares with voting rights. The company offers its patron members a full suite of comprehensive genomic profiling based mainly on next generation sequencing. Molecular alterations are identified based on rigorous testing with the aid of specially developed algorithms to increase accuracy and efficiency. The clinical relevance of the detected alterations is pulled from numerous databases using internally developed software. Relevance of findings to diagnosis, prognosis, selecting therapy, and predicting outcome are reported to members. The co-op model allows GTC to make the testing and information platform available to members at a lower cost because of a lower overhead. For more information, please visit https://genomictestingcooperative.com/.
Forward Looking Statements
All of the statements, expectations and assumptions contained in this press release are forward-looking statements. Such forward-looking statements are based on the GTC management’s current expectations and includes statements regarding the value of comprehensive genomic profiling, RNA profiling, DNA profiling, algorithms, therapy, the ability of testing to provide clinically useful information. All information in this press release is as of the date of the release, and GTC undertakes no duty to update this information unless required by law.
Company contact:
Jennifer Varca
Genomic Testing Cooperative.
(949) 540-9421